Daniel J Siegwart
Overview
Explore the profile of Daniel J Siegwart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao Y, Lian X, Sun Y, Sung Y, Vaidya A, Chen Z, et al.
Nat Mater
. 2025 Feb;
PMID: 40021827
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder...
2.
Lin L, Su K, Zhang X, Shi L, Yan X, Fu Q, et al.
Angew Chem Int Ed Engl
. 2025 Feb;
:e202500306.
PMID: 39929776
The progress of mRNA therapeutics underscores the imperative demand for the development of targeted delivery systems. While cationic polymers hold promise as genetic vectors, their poor in vivo efficacy and...
3.
Wu S, Yang Y, Lian X, Zhang F, Hu C, Tsien J, et al.
J Am Chem Soc
. 2024 Dec;
146(50):34733-34742.
PMID: 39655603
Lipid nanoparticles (LNPs) are an essential component of messenger RNA (mRNA) vaccines and genome editing therapeutics. Ionizable amino lipids, which play the most crucial role in enabling mRNA to overcome...
4.
Chai A, Siegwart D, Wang R
J Invest Dermatol
. 2024 Sep;
PMID: 39269387
Advances in sequencing technologies have facilitated the identification of the genes and mechanisms for many inherited skin diseases. Although targeted nucleic acid therapeutics for diseases in other organs have begun...
5.
Vaidya A, Moore S, Chatterjee S, Guerrero E, Kim M, Farbiak L, et al.
Adv Mater
. 2024 Jul;
36(35):e2313791.
PMID: 38973655
Inhibition of disease-causing mutations using RNA interference (RNAi) has resulted in clinically approved medicines with additional candidates in late stage trials. However, targetable tissues currently in preclinical development are limited...
6.
Sun Y, Chatterjee S, Lian X, Traylor Z, Sattiraju S, Xiao Y, et al.
Science
. 2024 Jun;
384(6701):1196-1202.
PMID: 38870301
In vivo genome correction holds promise for generating durable disease cures; yet, effective stem cell editing remains challenging. In this work, we demonstrate that optimized lung-targeting lipid nanoparticles (LNPs) enable...
7.
Lian X, Chatterjee S, Sun Y, Dilliard S, Moore S, Xiao Y, et al.
Nat Nanotechnol
. 2024 May;
19(9):1409-1417.
PMID: 38783058
Therapeutic genome editing of haematopoietic stem cells (HSCs) would provide long-lasting treatments for multiple diseases. However, the in vivo delivery of genetic medicines to HSCs remains challenging, especially in diseased...
8.
Cheng Q, Farbiak L, Vaidya A, Guerrero E, Lee E, Rose E, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(52):e2313009120.
PMID: 38109533
Genetic medicines have the potential to treat various diseases; however, certain ailments including inflammatory diseases and cancer would benefit from control over extracellular localization of therapeutic proteins. A critical gap...
9.
Wei T, Sun Y, Cheng Q, Chatterjee S, Traylor Z, Johnson L, et al.
Nat Commun
. 2023 Nov;
14(1):7322.
PMID: 37951948
Approximately 10% of Cystic Fibrosis (CF) patients, particularly those with CF transmembrane conductance regulator (CFTR) gene nonsense mutations, lack effective treatments. The potential of gene correction therapy through delivery of...
10.
Chen Z, Tian Y, Yang J, Wu F, Liu S, Cao W, et al.
J Am Chem Soc
. 2023 Oct;
145(44):24302-24314.
PMID: 37853662
Lipid nanoparticles (LNPs) represent the most clinically advanced nonviral mRNA delivery vehicles; however, the full potential of the LNP platform is greatly hampered by inadequate endosomal escape capability. Herein, we...